Showing results (31-40 of 89) with videos related to
Sort By:
Pageof 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2011
Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosingChristina I Herold, Vijaya Chadaram, Bercedis L Peterson, et al.Expert Review of Anticancer Therapy|June 28, 2021
The evolution of cyclin dependent kinase inhibitors in the treatment of cancerKomal Jhaveri, Howard A Burris Rd, Timothy A Yap, et al.Journal for Immunotherapy of Cancer|March 25, 2022
IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancerTimothy A Yap, Alberto Bessudo, Erika Hamilton, et al.JAMA Oncology|October 23, 2018
Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical TrialSylvia Adams, Jennifer R Diamond, Erika Hamilton, et al.Journal of the National Cancer Institute|July 13, 2026
Recurrence risk in HR-positive/HER2-negative early breast cancer: real-world US electronic health records studyPaolo Tarantino, Giuseppe Curigliano, Erika Hamilton, et al.JAMA Oncology|June 30, 2018
Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical TrialVirginia F Borges, Cristiano Ferrario, Nathalie Aucoin, et al.Investigational New Drugs|March 12, 2017
Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancersJennifer R Diamond, Barbara Goff, Martin D Forster, et al.Journal for Immunotherapy of Cancer|January 12, 2025
First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancerNehal J Lakhani, Daphne Stewart, Debra L Richardson, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 4, 2025
Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03Afshin Dowlati, Anne C Chiang, Andrés Cervantes, et al.Journal of Translational Medicine|February 14, 2012
Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]Erika Hamilton, Kimberly Blackwell, Amy C Hobeika, et al.Pageof 9